HealthPolitics

STAT+: Roche continues to look to China for new drugs

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/10/2026, 16:51:25 UTC.

Briefings

Roche announced a strategic partnership with Chinese company Hansoh Pharmaceutical to develop a portfolio of antibody-drug conjugates. This collaboration represents a significant expansion of Roche's drug development efforts in Asia, targeting the region's growing pharmaceutical market. The agreement involves joint development of new therapeutic agents, marking a key step in Roche's international expansion strategy.

Key points

• Roche and Hansoh Pharmaceutical Group signed a deal to develop a portfolio of antibody-drug conjugates in China.
• The partnership is part of Roche's broader strategy to expand operations in Asia and leverage Chinese pharmaceutical markets.

Context

Roche's international expansion strategy includes partnerships with Chinese companies to access local markets and develop new therapies. This collaboration represents a significant step in Roche's Asia expansion strategy.

Limitations

Evidence is limited to the announcement of the partnership between Roche and Hansoh Pharmaceutical. Specific details about the drug portfolio, development timeline, or commercial terms are not provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/10/2026, 16:54:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihsodydyvflk4vk7t3fhexn2v35ovuq2xfbw2whr2n3zgywuavita